Coherus Oncology reported third-quarter 2025 results and advanced its immuno-oncology strategy, expanding the clinical program for CHS-114, a cytolytic...

Zymeworks reported third-quarter 2025 results and a flurry of pipeline milestones, anchored by a $25 million development payment from...

Cellectis reported new clinical and financial milestones that push its allogeneic CAR-T portfolio toward pivotal testing and potential commercialization....

Surrozen reported third-quarter 2025 results and a tightened focus on ophthalmology, advancing two preclinical retinal candidates, SZN-8141 and SZN-8143,...

Exicure reported third-quarter 2025 results that underscore a high-risk pivot. The company ended the quarter with $4.4 million in...

In this interview, Christoph Bug, VP Global Medical Veeva, explains how Medical Affairs must evolve from tracking tasks to...

Relay Therapeutics reported third-quarter 2025 results, highlighted by steady execution across three clinical trials of RLY-2608 and the appointment...

Eton Pharmaceuticals posted another step-change quarter, reporting Q3 2025 product sales of $22.5 million, up 129% year over year...

Sana Biotechnology is refocusing its pipeline around two programs: SC451, a hypoimmune, iPSC‑derived pancreatic islet cell therapy for type...

Lisata Therapeutics reported a multifaceted third-quarter update anchored by advancing clinical signals for its tumor-penetrating peptide, certepetide, new partnerships...